I-Mab Reports Third Quarter 2024 Results [Yahoo! Finance]
I-MAB - American Depositary Shares (IMAB)
Company Research
Source: Yahoo! Finance
On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024 ROCKVILLE, Md. Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended September 30, 2024, and highlighted recent pipeline progress and business updates. "I-Mab is making excellent progress in advancing the development of our pipeline projects, supported by our strong cash balance, streamlined operating model, and a focused in-licensing strategy," said Dr. Sean Fu , CEO and Board Member of I-Mab. "In addition, Phase 1 data presented this year for
Show less
Read more
Impact Snapshot
Event Time:
IMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMAB alerts
High impacting I-MAB - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMAB
News
- I-Mab to Participate at the Piper Sandler Healthcare ConferencePR Newswire
- I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- I-Mab Reports Third Quarter 2024 ResultsPR Newswire
- I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive OfficerPR Newswire
- I-Mab to Release Q3 2024 Financial Results on November 14, 2024PR Newswire
IMAB
Earnings
- 11/14/24 - Miss
IMAB
Sec Filings
- 11/14/24 - Form 6-K
- 11/6/24 - Form 6-K
- 11/5/24 - Form 6-K
- IMAB's page on the SEC website